Drugs / TQA2225/AP025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06569524 | Sep 2023 → Dec 2026 expected | metabolic dysfunction-associated steatohepatitis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQA2225/AP025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06569524 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human FGF21-Fc Fusion Protein for Injection” NCT06569524 ↗ |
| Route | Subcutaneous | “administered 25mg by subcutaneous (SC) injection” NCT06569524 ↗ |